ArticleAntimicrobial agents and chemotherapy2018
A Novel Piperazine-Based Drug Lead for Cryptosporidiosis from the Medicines for Malaria Venture Open-Access Malaria Box.
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 66 citations in OpenAlex.
- Unravelling the synergistic potential of Olibanum extract and Bacillus clausii in combating intestinal cryptosporidiosis in immunosuppressed mice.PLoS neglected tropical diseases · 2026Article
- Genomic heterogeneity of NAD(P)H dehydrogenase predisposes Cryptosporidium to clofazimine resistance.Nature microbiology · 2026Article
- Article
- Pathogenicity and virulence ofVirulence · 2025Review
- Norditerpene Natural Products from Subterranean Fungi with Anti-Parasitic Activity.Microorganisms · 2025Article
- Widespread genomic heterogeneity at the type II NAD(P)H dehydrogenase locus predisposesbioRxiv : the preprint server for biology · 2025Article
- Synthesis of β-fluoropyrrolidines designed to reduce hERG affinity in a class of antiparasitic compounds.ChemistrySelect · 2025Article
- Discovery of an Orally Efficacious Pyrazolo[3,4-Journal of medicinal chemistry · 2025Article
- Cryptosporidium PI(4)K inhibitor EDI048 is a gut-restricted parasiticidal agent to treat paediatric enteric cryptosporidiosis.Nature microbiology · 2024Article
- Article
- Identification of potent and orally efficacious phosphodiesterase inhibitors in Cryptosporidium parvum-infected immunocompromised male mice.Nature communications · 2024Article
- Pharmacokinetics and tissue distribution of LN002, a new compound alternative oxidase inhibitor againstFrontiers in pharmacology · 2024Article
- Structure-Activity Relationship Studies of the Aryl Acetamide Triazolopyridazines againstJournal of medicinal chemistry · 2023Article
- Article
- Structure-Activity relationships of replacements for the triazolopyridazine of Anti-Cryptosporidium lead SLU-2633.Bioorganic & medicinal chemistry · 2023Article
- Past, current, and potential treatments for cryptosporidiosis in humans and farm animals: A comprehensive review.Frontiers in cellular and infection microbiology · 2023Review
- The Marine Compound Tartrolon E Targets the Asexual and Early Sexual Stages ofMicroorganisms · 2022Article
- An update onJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2022Review
- Live imaging of the Cryptosporidium parvum life cycle reveals direct development of male and female gametes from type I meronts.PLoS biology · 2022Article
- High-Throughput Screening of a Marine Compound Library Identifies Anti-Marine drugs · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
Abstract
Cryptosporidiosis causes life-threatening diarrhea in children under the age of 5 years and prolonged diarrhea in immunodeficient people, especially AIDS patients. The standard of care, nitazoxanide, is modestly effective in children and ineffective in immunocompromised individuals. In addition to the need for new drugs, better knowledge of drug properties that drive
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.